These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 23034406)

  • 21. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
    Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
    J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
    Schmidinger M; Zielinski CC; Vogl UM; Bojic A; Bojic M; Schukro C; Ruhsam M; Hejna M; Schmidinger H
    J Clin Oncol; 2008 Nov; 26(32):5204-12. PubMed ID: 18838713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
    Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thyroid dysfunction in patients treated with sunitinib or sorafenib.
    Clemons J; Gao D; Naam M; Breaker K; Garfield D; Flaig TW
    Clin Genitourin Cancer; 2012 Dec; 10(4):225-31. PubMed ID: 23017335
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Metastasized renal cell carcinoma. Measurement of plasma levels of the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib].
    Keil C; Götze L; Olbert P; Hofmann R; Nockher WA; Hegele A
    Urologe A; 2015 Jun; 54(6):811-8. PubMed ID: 25503897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma.
    Flörcken A; Takvorian A; Van Lessen A; Singh A; Hopfenmüller W; Dörken B; Pezzutto A; Westermann J
    Anticancer Drugs; 2012 Mar; 23(3):298-302. PubMed ID: 22156795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805.
    Haas NB; Manola J; Ky B; Flaherty KT; Uzzo RG; Kane CJ; Jewett M; Wood L; Wood CG; Atkins MB; Dutcher JJ; Wilding G; DiPaola RS
    Clin Cancer Res; 2015 Sep; 21(18):4048-54. PubMed ID: 25967143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of the first trial assessing adjuvant tyrosine kinase inhibitors in renal cell carcinoma do not reASSURE.
    Ouzaid I; Bensalah K
    Eur Urol; 2015 Sep; 68(3):542-3. PubMed ID: 26001611
    [No Abstract]   [Full Text] [Related]  

  • 29. A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.
    Alasker A; Meskawi M; Sun M; Ismail S; Hanna N; Hansen J; Tian Z; Bianchi M; Perrotte P; Karakiewicz PI
    Cancer Treat Rev; 2013 Jun; 39(4):388-401. PubMed ID: 23317510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Professor Shukui Qin: patient reported outcomes in study of axitinib or sorafenib in Asian patients with metastatic renal cell carcinoma.
    Qin S; Zhang S
    Chin Clin Oncol; 2015 Mar; 4(1):15. PubMed ID: 25841722
    [No Abstract]   [Full Text] [Related]  

  • 31. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
    Erdem L; Giovannetti E; Leon LG; Honeywell R; Peters GJ
    Curr Top Med Chem; 2012; 12(15):1649-59. PubMed ID: 22978339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects.
    Kondo T; Hashimoto Y; Kobayashi H; Iizuka J; Nishikawa T; Nakano M; Tanabe K
    Jpn J Clin Oncol; 2010 Dec; 40(12):1173-9. PubMed ID: 20696817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
    Santoni M; Conti A; Porta C; Procopio G; Sternberg CN; Basso U; De Giorgi U; Bracarda S; Rizzo M; Ortega C; Massari F; Iacovelli R; Derosa L; Masini C; Milella M; Di Lorenzo G; Atzori F; Pagano M; Buti S; De Vivo R; Mosca A; Rossi M; Paglino C; Verzoni E; Cerbone L; Muzzonigro G; Falconi M; Montironi R; Burattini L; Santini D; Cascinu S
    J Urol; 2015 Jan; 193(1):41-7. PubMed ID: 25046616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib.
    Niinivirta M; Enblad G; Edqvist PH; Pontén F; Dragomir A; Ullenhag GJ
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):961-970. PubMed ID: 28260162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
    Stein MN; Flaherty KT
    Clin Cancer Res; 2007 Jul; 13(13):3765-70. PubMed ID: 17606705
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
    Santoni M; Conti A; Massari F; Arnaldi G; Iacovelli R; Rizzo M; De Giorgi U; Trementino L; Procopio G; Tortora G; Cascinu S
    Int J Cancer; 2015 Jan; 136(1):1-10. PubMed ID: 24415642
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sorafenib and sunitinib for elderly patients with renal cell carcinoma.
    Derbel Miled O; Dionne C; Terret C; Segura-Ferlay C; Flechon A; Neidhart EM; Negrier S; Droz JP
    J Geriatr Oncol; 2013 Jul; 4(3):255-61. PubMed ID: 24070463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maturing of renal cancer therapeutics.
    Stadler WM
    J Clin Oncol; 2014 Mar; 32(8):722-4. PubMed ID: 24516015
    [No Abstract]   [Full Text] [Related]  

  • 39. Two new drugs for renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Feb; 49(1255):18-20. PubMed ID: 17325624
    [No Abstract]   [Full Text] [Related]  

  • 40. Sorafenib induced eruptive melanocytic lesions.
    Uhlenhake EE; Watson AC; Aronson P
    Dermatol Online J; 2013 May; 19(5):18184. PubMed ID: 24011281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.